Telix Pharmaceuticals (NASDAQ:TLX) Cut to Sector Perform at Royal Bank Of Canada

Royal Bank Of Canada downgraded shares of Telix Pharmaceuticals (NASDAQ:TLX) from an outperform rating to a sector perform rating in a report published on Friday, Marketbeat.com reports.

Several other research analysts also recently commented on TLX. Wedbush reissued an “outperform” rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Monday, July 6th. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Monday, April 20th. Citigroup reduced their price target on shares of Telix Pharmaceuticals from $22.50 to $22.00 and set a “buy” rating on the stock in a research note on Tuesday, July 7th. Wall Street Zen raised shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $20.40.

Telix Pharmaceuticals Price Performance

Shares of TLX stock opened at $10.46 on Friday. The business has a fifty day simple moving average of $10.36 and a 200 day simple moving average of $9.07. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. Telix Pharmaceuticals has a twelve month low of $6.28 and a twelve month high of $16.94.

Insiders Place Their Bets

In other news, CEO Christian Behrenbruch acquired 33,435 shares of Telix Pharmaceuticals stock in a transaction that occurred on Wednesday, April 29th. The shares were acquired at an average price of $14.87 per share, for a total transaction of $497,178.45. Following the transaction, the chief executive officer directly owned 20,742,935 shares of the company’s stock, valued at approximately $308,447,443.45. The trade was a 0.16% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Institutional Trading of Telix Pharmaceuticals

A number of hedge funds have recently made changes to their positions in TLX. Rhumbline Advisers grew its holdings in shares of Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after purchasing an additional 1,392 shares during the last quarter. Bank of America Corp DE raised its holdings in Telix Pharmaceuticals by 523.8% in the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after buying an additional 8,423 shares during the last quarter. XTX Topco Ltd bought a new position in Telix Pharmaceuticals in the 4th quarter valued at approximately $89,000. XY Capital Ltd acquired a new stake in Telix Pharmaceuticals during the 1st quarter worth approximately $120,000. Finally, IHT Wealth Management LLC acquired a new stake in Telix Pharmaceuticals during the 2nd quarter worth approximately $213,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.